Artemis Medicare Services will participate in the EMKAY Confluence 2026 investor conference on August 13, 2026, providing a direct channel for dialogue with institutional investors and equity analysts. The event, titled 'India: Full Throttle Ahead,' serves as an annual forum for market participants to assess corporate strategies and financial outlooks within the Indian healthcare sector.

The disclosure was made on August 10, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory requirement ensures timely transparency regarding material events that may influence investor sentiment or trading activity. The company has notified both the National Stock Exchange of India Limited and BSE Limited of its scheduled appearance.

Event Details

The conference will be held in Mumbai in a physical format, facilitating face-to-face interactions between company representatives and the investment community. This mode of engagement allows for more detailed discussions compared to virtual presentations, enabling investors to probe deeper into operational metrics and strategic initiatives.

Regulatory Compliance

Poonam Makkar, Company Secretary and Compliance Officer of Artemis Medicare Services Limited, signed the disclosure letter. The filing explicitly notes that the schedule is subject to change due to exigencies on the part of analysts, investors, or the company. Such contingencies are standard in investor relations calendars but require immediate communication if alterations occur to maintain regulatory compliance.

Strategic Context

Participation in high-profile investor conferences like EMKAY Confluence signals management's intent to reinforce visibility among domestic and international fund managers. For healthcare providers, these platforms are critical for communicating service expansion plans, patient volume trends, and margin sustainability amidst evolving reimbursement landscapes. The physical nature of the event underscores the importance Artemis places on direct stakeholder engagement during this fiscal period.

Artemis Medicare Services reported a 48.3% year-on-year increase in consolidated net profit after tax (PAT) to ₹3,144.27 lacs for the quarter ended June 30, 2026 (Q1FY27), driven by robust revenue growth and significant margin expansion. Revenue from operations rose 12.7% to ₹28,732.35 lacs, while the EBITDA margin widened to 21.5% from 19.0% in the corresponding period last year. The strong profitability underscores effective operational leverage as patient volumes and average revenue per occupied bed improved across its flagship facilities. In a separate development, the Board of Directors approved an expansion plan for Tower IV at its Gurugram hospital, adding over 200 beds focused on pediatric and women’s health services.

The results were approved by the Board on August 3, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited financial statements were reviewed by statutory auditors T R Chadha & Co LLP, who issued an unmodified conclusion under Regulation 33. The consolidated figures include the results of its subsidiary, Artemis Cardiac Care Private Limited, which reported total assets of ₹2,260.47 lacs and net profit of ₹37.75 lacs for the quarter.

Financial Performance Highlights

On a standalone basis, revenue from operations grew 12.9% year-on-year to ₹28,200.97 lacs, with PAT rising 45.0% to ₹3,105.11 lacs. The standalone EBITDA margin improved to 21.6% from 19.1% in Q1FY26. Consolidated total income stood at ₹29,269.74 lacs. Other income declined by 22.4% to ₹537.39 lacs, primarily due to the utilization of International Finance Corporation (IFC) funds towards expansion projects. Finance costs decreased by 12.5% to ₹645.99 lacs, further supporting bottom-line growth.

The following table summarizes the key consolidated financial metrics for Q1FY27:

Operative expenses increased by 6.7% to ₹16,776.44 lacs, while employee benefit expenses rose 11.6% to ₹4,283.64 lacs. The company’s paid-up equity share capital remained unchanged at ₹1,583.06 lacs.

Operational Metrics and Growth Drivers

The flagship hospital in Gurugram demonstrated strong operational health, with inpatient volumes increasing 11.4% to 9,181. Occupancy rates improved to 65.7%, up 443 basis points year-on-year. The Average Revenue Per Occupied Bed (ARPOB) rose 7.4% to ₹85,690, reflecting a high-acuity clinical mix. Average Length of Stay reduced slightly to 3.54 days from 3.67 days, indicating enhanced efficiency.

Revenue from overseas patients increased by 8.6% to ₹7,650.52 lacs, contributing approximately 27.5% to the Gurugram hospital’s revenue. About 60% of total revenue is derived from high-acuity specialties such as oncology, transplants, and robotic surgery. The company has established 14 Centres of Excellence across more than 40 specialties.

Capacity Expansion Roadmap

The Board approved the addition of 200+ beds in Tower IV at the Sector-51, Gurugram facility, dedicated to quaternary pediatric care and advanced gynecology & women’s health services. This expansion aims to address growing demand for specialized neonatal, pediatric intensive care, and high-risk pregnancy management. The project requires an investment of approximately ₹160–180 crore, financed through internal accruals and debt, with completion expected within two years.

Other key initiatives include:

• Raipur Hospital: A 300+ bed super speciality hospital commenced operations in July 2026.
• South Delhi Hospital: An MSA was executed for a 650+ bed facility expected to commence operations by FY29.
• Overseas Operations: The company operates an 80-bed facility in Mauritius and announced a 110-bed facility in FY27.

What the Numbers Show

The divergence between revenue growth (12.7%) and PAT growth (48.3%) highlights significant operating leverage achieved in Q1FY27. The EBITDA margin expansion of 250 basis points suggests that fixed costs are being spread over a larger volume base while variable costs are managed effectively. Despite a decline in other income due to IFC fund utilization for expansion, core operational earnings remained resilient. The strategic focus on high-acuity cases and international patients continues to drive premium ARPOB, supporting long-term value creation.